Pfizer CEO Albert Bourla announced Monday that he has tested positive for COVID-19 — and praised his company’s vaccines while announcing his diagnosis.
“I would like to let you know that I have tested positive for #COVID19. I am thankful to have received four doses of the Pfizer-BioNTech vaccine, and I am feeling well while experiencing very mild symptoms. I am isolating and have started a course of Paxlovid,” he said in a series of tweets.
“We have come so far in our efforts to battle this disease that I am confident I will have a speedy recovery,” Bourla said. “I am incredibly grateful for the tireless efforts of my Pfizer colleagues who worked to make vaccines and treatments available for me and people around the world.”
We have come so far in our efforts to battle this disease that I am confident I will have a speedy recovery. I am incredibly grateful for the tireless efforts of my Pfizer colleagues who worked to make vaccines and treatments available for me and people around the world.
— Albert Bourla (@AlbertBourla) August 15, 2022
Bourla concluded by focusing on Paxlovid, a drug developed by Pfizer that was also given to President Joe Biden when he had the virus last month.
“Paxlovid is not approved, but is authorized for emergency use by the FDA to treat mild-to-moderate COVID-19 in high-risk patients 12+, weighing at least 40 kg [88 pounds], with positive results of SARS-CoV-2 viral testing,” he wrote.
Paxlovid is not approved, but is authorized for emergency use by the FDA to treat mild-to-moderate COVID-19 in high-risk patients 12+, weighing at least 40 kg, with positive results of SARS-CoV-2 viral testing. See safety info: https://t.co/XqokFVKBC7.
— Albert Bourla (@AlbertBourla) August 15, 2022
Last week, the U.S. Centers for Disease Control and Prevention revised its guidelines for those who test positive for COVD-19.
Chief among these guidelines was that unvaccinated individuals no longer need to quarantine after testing positive.
Subscribe
Gain access to all our Premium contents.More than 100+ articles.
